explore -WSS

explore

author：focus 2025-09-07 11:11:45 - browse：1287

A sign of The Cigna Group in front of trees with orange and green leaves — insurance overage from STAT — Joe Buglewicz/Bloomberg

Cigna and Humana are in discussions to merge, a potential move that would create a health insurance and prescription drug benefits titan with approximately $300 billion of annual revenue.

A proposed transaction would almost certainly prompt a close review from antitrust enforcers at the Department of Justice and the Federal Trade Commission. A merged Cigna-Humana would further consolidate the market for pharmacy benefit managers. PBMs are companies that serve as the controversial middlemen of drug pricing negotiations, and of the four largest, two are owned by Cigna and Humana.

The Wall Street Journal first reported the talks between Cigna and Humana on Wednesday, citing sources close to the situation. Wendell Potter, a health insurance whistleblower who used to work at Cigna, also wrote about merger discussions between Cigna and Humana on his blog Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Medicare Advantage today, explained in one chart

WSS

How digital therapeutics firms are pivoting after Pear's bankruptcy

Does Paxlovid work in people vaccinated against Covid

Study suggests new cause of Down syndrome: cells linked to aging

eGenesis tests gene

Dewpoint Therapeutics lays off staff after losing partnerships

Copay coupons to count toward deductibles, after Biden court move

hotspot

explore

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

A preacher's new calling: Diversifying neuroscience research

Novavax promises a turnaround & Lilly roils the obesity market

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Alkermes shareholders re

Humana cuts profit projections as Medicare Advantage costs soar

Cancer drug shortages should be causing more outrage

Profiling embryos to choose those with higher IQs is almost a reality

What does generative AI mean for health care? We asked experts

FDA early review: GLP

hotspot

FDA clears AI tool for detecting skin cancer

My yearlong odyssey to get my son’s ADHD medication covered

Allen Institute goes after foundational questions, CEO Costa says

Parkinson’s finding may lead to tests and, someday, treatments

FDA early review: GLP

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

entertainment

focus

explore

focus